ABUS - Arbutus Biopharma Corporation
| Previous Close | 1.4600 |
| Open | 1.4300 |
| Bid | 1.3800 x 1000 |
| Ask | 1.9500 x 1100 |
| Day's Range | 1.3800 - 1.4700 |
| 52 Week Range | 1.3800 - 11.2500 |
| Volume | 212,355 |
| Avg. Volume | 458,631 |
| Market Cap | 81.042M |
| Beta (3Y Monthly) | 2.02 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.7900 |
| Earnings Date | Nov 4, 2019 - Nov 8, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.32 |
- GlobeNewswire
Arbutus Biopharma Appoints Andrew Cheng, M.D., Ph.D., to its Board of Directors
Arbutus Biopharma Corporation (ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Andrew Cheng, M.D., Ph.D., has been appointed to the Arbutus Board of Directors effective August 17, 2019. “We are pleased to welcome Dr. Cheng to the Arbutus Board,” said Dr. Frank Torti, Chairman of the Arbutus Board of Directors. Dr. Cheng is currently President and Chief Executive Officer of Akero Therapeutics (Nasdaq:AKRO), a biotechnology company focused on the development of transformational treatments for non-alcoholic steatohepatitis (NASH) and other serous metabolic diseases.
- GlobeNewswire
Arbutus to Participate at Wedbush PacGrow Healthcare Conference
WARMINSTER, Pa., Aug. 06, 2019 -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that.
- Zacks
Arbutus Biopharma (ABUS) Reports Q2 Loss, Lags Revenue Estimates
Arbutus (ABUS) delivered earnings and revenue surprises of -31.43% and -20.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Arbutus Reports Second Quarter 2019 Financial Results and Provides Corporate Update
- Appointed William Collier, with decades of leadership experience in antivirals, President & CEO - Announced preliminary Phase 1a/1b clinical trial results demonstrating.
- GlobeNewswire
Arbutus to Report Second Quarter 2019 Financial Results
WARMINSTER, Pa., July 29, 2019 -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that.
- Zacks
Will Arbutus Biopharma (ABUS) Report Negative Q2 Earnings? What You Should Know
Arbutus (ABUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
Arbutus Announces Preliminary Phase 1a/1b Clinical Trial Results for AB-506, an Oral Capsid Inhibitor in Development for People with Chronic Hepatitis B
Arbutus Biopharma Corporation (ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced preliminary results from a Phase 1a/1b clinical trial in healthy subjects and two cohorts of chronic hepatitis B (CHB) subjects who received AB-506 monotherapy. A detailed analysis of these Phase 1a/1b preliminary results will be submitted for presentation at a future scientific meeting later this year. William H. Collier, President and Chief Executive Officer of Arbutus, stated, “Preliminary results from this first Phase 1a/1b clinical trial demonstrate that AB-506 is a potent oral capsid inhibitor.
- Insider Monkey
Here’s What Hedge Funds Think About Arbutus Biopharma Corp (ABUS)
Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that's why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]
- Benzinga
The Daily Biotech Pulse: Roche's Flu Drug Aces Late-Stage Trial, Acura Outlicenses Pain Medication, Neuronetics Gets New Finance Chief
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 2) ANI Pharmaceuticals Inc Common Stock (NASDAQ: ANIP ) ...
- GlobeNewswire
Arbutus Sells Part of its ONPATTRO™ (patisiran) Royalty Interest to OMERS
Arbutus Biopharma Corporation (ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced the sale of part of its royalty interest on future global net sales of ONPATTRO™ (patisiran), an RNA interference (RNAi) therapeutic currently being sold by Alnylam Pharmaceuticals, Inc. (ALNY) (Alnylam), to OMERS, the defined benefit pension plan for municipal employees based in the Province of Ontario, Canada. ONPATTRO utilizes Arbutus’s lipid nanoparticle (LNP) technology, which was licensed to Alnylam in November 2012.
- Zacks
Arbutus Gets Clearance to Initiate Hepatitis Study, Stock Up
Arbutus (ABUS) surges on clearance for a clinical study to evaluate its RNAi agent, AB-729 as a treatment for hepatitis B virus.
- GlobeNewswire
Arbutus receives regulatory clearance to initiate Phase 1a/1b Clinical Trial of AB-729
Arbutus Biopharma Corporation (ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced it has received regulatory clearance to initiate a Phase 1a/1b clinical trial of AB-729, Arbutus’ subcutaneously-administered RNA interference (RNAi) agent. AB-729 employs a single RNAi trigger that has been shown in preclinical models to span all HBV transcripts, reduce all viral antigens, including hepatitis B surface antigen (HBsAg) expression, and inhibit HBV replication. This RNAi agent uses Arbutus’ proprietary covalently conjugated N-acetylgalactosamine (GalNAc) hepatocyte targeting technology which is expected to allow for once-a-month dosing.
- GlobeNewswire
Arbutus Appoints William Collier as Next President & CEO and Announces Retirement of Current President & CEO, Mark J. Murray Ph.D.
Arbutus Biopharma Corporation (ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced the appointment of William H. Collier as President and Chief Executive Officer, effective June 24th. Mr. Collier has also been appointed as a member of the Board of Directors of Arbutus, effective June 24th, to fill the vacancy created by the resignation of Mark J. Murray, Ph.D., from the Board of Directors. Dr. Murray will continue to serve as President and Chief Executive Officer and as a member of the Board of Directors until his retirement on June 23rd.
- GlobeNewswire
Arbutus to Participate at JMP Securities Life Sciences Conference
WARMINSTER, Pa., June 13, 2019 -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that.
- Simply Wall St.
Is Arbutus Biopharma Corporation (NASDAQ:ABUS) Excessively Paying Its CEO?
Mark Murray became the CEO of Arbutus Biopharma Corporation (NASDAQ:ABUS) in 2008. This report will, first, examine...
- GlobeNewswire
Arbutus to Present at Upcoming May 2019 Conferences
WARMINSTER, Pa., May 13, 2019 -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that.
- Zacks
Arbutus Biopharma (ABUS) Reports Q1 Loss, Misses Revenue Estimates
Arbutus (ABUS) delivered earnings and revenue surprises of -51.61% and -40.43%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press
Arbutus: 1Q Earnings Snapshot
On a per-share basis, the Burnaby, British Columbia-based company said it had a loss of 47 cents. The biopharmaceutical company posted revenue of $700,000 in the period. In the final minutes of trading ...
- GlobeNewswire
Arbutus Reports First Quarter 2019 Financial Results and Provides Corporate Update
Top-line safety and efficacy results from an interim analysis of the initial Phase 1a/1b clinical trial of AB-506, a proprietary oral capsid inhibitor, expected in July 2019.
- GlobeNewswire
Arbutus to Report First Quarter 2019 Financial Results
WARMINSTER, Pa., April 29, 2019 -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that.
- Zacks
Arbutus Biopharma (ABUS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Arbutus (ABUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
4 Drug/Biotech Stocks Making a Mark in RNAi Therapeutics
We take a look at companies, which have been developing treatments for various diseases using RNAi technology.
- Simply Wall St.
Arbutus Biopharma Corporation (NASDAQ:ABUS): Will The Growth Last?
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! In December 2018, Arbutus Biopharma Corporation (NASDAQ:ABUS) released its latest earnings announcement, which signalled...
Motley FoolArbutus Biopharma Corp (ABUS) Q4 2018 Earnings Conference Call Transcript
ABUS earnings call for the period ending December 31, 2018.
